Table 5 Effect of the APOA5 rs662799 polymorphism on plasma triglyceride levels in ESKD patients with and without CVD
Group | Genotype | TG (mmol/l) | Difference vs. TT | 95% CI | p |
|---|---|---|---|---|---|
ESKD CVD +  | TT (n = 423) | 1.29 ± 1 | ref |  |  |
TC (n = 105) | 1.82 ± 1.49 | -0.530 | -0.78 to -0.27 | 0.001 | |
CC (n = 24) | 2.39 ± 1.36 | -1.100 | -1.56 to -0.63 |  > 0.001 | |
TC + CC (n = 129) | 2.11 ± 1.42 | -0.820 | -1.05 to -0.58 |  > 0.001 | |
ESKD CVD- | TT (n = 221) | 1.07 ± 1.20 | ref |  |  |
TC (n = 23) | 1.63 ± 1.46 | -0.500 | -1.08 to -0.03 | 0.038 | |
CC (n = 4) | 2.19 ± 1.39 | -1.120 | -2.31 to 0.07 | 0.066 | |
TC + CC (n = 27) | 1.91 ± 1.42 | -0.840 | -1.33 to 0.34 | 0.009 |